Vumerity was approved by the U.S. Food and Drug Administration in October 2019 as a treatment for adults with relapsing forms of MS. These types include clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis.
Based on animal studies, Vumerity use during pregnancy can cause harm to a developing fetus. Patients who become or plan to become pregnant while on the medication should discuss this issue with their healthcare provider.
Patients on Vumerity do not have to stop drinking alcohol completely, but they should not drink any at the same time they take the medication. This is because alcohol can reduce the amount of the medication’s active ingredient that is absorbed by the body. Patients should talk with their healthcare team to understand when and how much alcohol is safe for them to drink.
As each person reacts differently to a given treatment, there is no standard timeline for how soon Vumerity is expected to start working. Patients should ask their healthcare providers how the medication can help in their specific case.
While weight gain and hair loss were not reported in clinical trials as side effects of Vumerity, some patients who received the active ingredient after the medication’s approval have experienced hair loss. Patients who experience unanticipated effects of treatment should discuss these with their healthcare team.
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.